Neogen Corp
NASDAQ:NEOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (23.7), the stock would be worth $6.59 (30% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 33.9 | $9.42 |
0%
|
| 3-Year Average | 23.7 | $6.59 |
-30%
|
| 5-Year Average | 27.2 | $7.55 |
-20%
|
| Industry Average | 12.9 | $3.58 |
-62%
|
| Country Average | 14.4 | $3.99 |
-58%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$2.7B
|
/ |
Mar 2026
$79.1m
|
= |
|
|
$2.7B
|
/ |
May 2026
$174.1m
|
= |
|
|
$2.7B
|
/ |
May 2027
$188.5m
|
= |
|
|
$2.7B
|
/ |
May 2028
$199.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Neogen Corp
NASDAQ:NEOG
|
2.1B USD | 33.9 | -3.4 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.4B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 28.1 | 38.7 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.1B CHF | 14.5 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
96.5B DKK | 12.7 | 24 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.9B USD | 14.8 | 34 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 11.9 | 34.3 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 16.9 | -15.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -83.8 | -37.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
868.9B JPY | 23.2 | 49.1 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 14.6 | 22.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Neogen Corp
Glance View
Founded in 1982, Neogen Corp. has steadily carved out its niche at the intersection of food safety and animal health, positioning itself as a vital player in agricultural diagnostics. The company's journey began in Lansing, Michigan, where it initially focused on innovative solutions to meet the growing demands of food safety and quality testing. By developing rapid tests for detecting foodborne bacteria and allergens, Neogen tapped into a critical market, addressing the increasing concerns about food safety amidst a complex global supply chain. This foundation in diagnostics set the stage for the growth Neogen would see over the ensuing decades. As Neogen expanded, it strategically diversified its offerings, moving beyond food safety into the broader realm of animal health. This expansion was not merely about developing products; it was about advancing the means by which farms and food producers monitor and ensure the health of their livestock and crops. The company's profits flow from the sale of its diagnostic products, which help minimize risks associated with food contamination and animal diseases. By providing a suite of solutions, from DNA testing for genetic traits and diseases in cattle to disinfectants and rodenticides that maintain farm hygiene, Neogen creates value for its clients by increasing their operational efficiency and safeguarding public health. This strategic blend of food safety and animal health products places Neogen at the heart of modern agricultural and food production systems, where safety and efficiency are paramount.